Yttrium-90-labeled human macroaggregated albumin for internal radiotherapy: combined use with DTPA.
The aim of this study was to investigate the possibility of yttrium-90-labeled human macroaggregated albumin (90Y-MAA) as an internal radiotherapeutic agent for whole-lung irradiation in combination with diethylenetriamine pentaacetic acid (DTPA). The influence of trisodium calcium DTPA (CaNa3DTPA) on the radioactivity of 90Y-MAA in serum was investigated in vitro. The effect of CaNa3DTPA on the biodistribution of radioactivity in normal mice intraveneously injected with 90Y-MAA was examined. CaNa3DTPA could deprive in vitro radioactivity of 90Y-MAA in 48-h incubation. Most of the radioactivity (>90% injected dose per lung) was observed at murine lung after injection of 90Y-MAA. Pulmonary radioactivity was cleared within 72 h postinjection, whereas the radioactivities in the bone, liver, kidneys, and spleen increased with a peak at 48 h. CaNa3DTPA-treatment reduced the in vivo radioactivities in bone, liver, and kidneys without influence on the radioactivity of lung. In conclusion, combined use of CaNa3DTPA enables 90Y-MAA to be used as a radiopharmaceutical for internal irradiation against whole lung.
Watanabe
N
N
Division of Advanced Technology for Medical Imaging, National Institute of Radiological Sciences, Chiba, Japan. w_nao@nirs.go.jp
Oriuchi
N
N
Endo
K
K
Inoue
T
T
Tanada
S
S
Murata
H
H
Sasaki
Y
Y
D000418:Albumins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D002614:Chelating Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008168:Lung / Q000378:metabolism / Q000528:radiation effects; D051379:Mice; D008807:Mice, Inbred BALB C; D004369:Pentetic Acid / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D014018:Tissue Distribution; D015021:Yttrium Radioisotopes / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use
D000418:Albumins; D002614:Chelating Agents; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; C403884:yttrium-90 macroaggregated albumin; D004369:Pentetic Acid